Gravar-mail: TMOD-03. GAINING A MECHANISTIC UNDERSTANDING OF THERAPY EVASION FROM DUAL MAPK PATHWAY INHIBITION IN A SYNGENEIC BRAFV600E MUTANT CDKN2A DELETED MOUSE MODEL TO PREEMPT RESISTANCE IN PATIENTS WITH BRAFV600E MUTANT PEDIATRIC GLIOMA